AzTrials
AzTrials

Advanced CholangiocarcinomaPhase 1NCT04088188

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

A Phase 1 study testing Cisplatin, Gemcitabine and Ivosidenib in people with Advanced Cholangiocarcinoma and Metastatic Cholangiocarcinoma, run by Academic and Community Cancer Research United at 7 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This phase I trial studies the side effects and best dose of gemcitabine and cisplatin when given together with ivosidenib or pemigatinib in treating patients with cholangiocarcinoma that cannot be removed with surgery (unresectable) or has spread to other places in the body (metastatic). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Cisplatin, Gemcitabine and Ivosidenib
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8 participants
Where
7 sitesUnited States
Study dates
25 Jan 2021to 1 Dec 2023
Phase
Phase 1
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Histopathological diagnosis (fresh) or banked tumor biopsy sample collected within the last 3 years from the registration date consistent with nonresectable or metastatic cholangiocarcinoma and are not eligible for curative resection, transplantation, or ablative therapies
  • Documented disease without any evidence of progression following at least 3 cycles of standard-of-care chemotherapy including gemcitabine and cisplatin as part of first-line systemic therapy; NOTE: Only patients receiving standard-of-care chemotherapy including gemcitabine and cisplatin as first-line therapy for unresectable or metastatic cholangiocarcinoma will be permitted to enroll in this trial. Prior systemic adjuvant chemotherapy is allowed as long as there was no evidence of recurrence within 6 months of completing the adjuvant therapy
  • Molecular testing result from Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (using fresh tumor biopsy or most recent banked tumor tissue available) confirming that the tumor tissue has at least one of the following:
  • IDH1 gene mutation (R132C/L/G/H/S mutation)
  • FGFR2 gene alteration
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
Show all 26Show fewer
  • Life expectancy >= 3 months
  • At least one evaluable and measurable lesion by RECIST criteria prior to beginning chemotherapy with gemcitabine and cisplatin
  • NOTE: Subjects who have received prior local therapy (including but not limited to embolization, chemoembolization, radiofrequency ablation, hepatic arterial infusion, or radiation therapy) are eligible provided measurable disease falls outside of the treatment
  • Recovered from toxicities associated with prior anticancer therapy to baseline unless stabilized under medical management
  • Absolute neutrophil count >= 1,500/mm^3 (obtained =< 21 days prior to registration)
  • Platelet count >= 100,000/mm^3 (obtained =< 21 days prior to registration)
  • Hemoglobin >= 8 g/dL (obtained =< 21 days prior to registration)
  • Serum total bilirubin =< 2.0 x upper limit of normal (ULN), unless considered due to Gilbert's disease. If Gilbert's disease or disease involving liver, serum total bilirubin =< 2.5 x ULN (obtained =< 21 days prior to registration)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5.0 x ULN in the presence of liver metastases (obtained =< 21 days prior to registration)
  • Serum creatinine < 1.5 x ULN OR creatinine clearance >= 50 mL/min based on the Cockcroft-Gault glomerular filtration rate (GFR) estimation (obtained =< 21 days prior to registration)
  • Serum phosphate =< institutional ULN and potassium within institutional normal range for Arm B only (obtained =< 21 days prior to registration)
  • NOTE: Supplemental potassium may be used to correct potassium prior to registration
  • Negative serum pregnancy test done =< 7 days prior to registration for women of childbearing potential only
  • NOTE: Females of reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy, or tubal occlusion or who have not been naturally postmenopausal (i.e., who have not menstruated) for >= 24 consecutive months (i.e., have not had menses at any time in the preceding 24 consecutive months)
  • Women of reproductive potential and fertile men must agree to use 2 effective forms of contraception (including at least 1 barrier form) from the time of giving informed consent throughout the study and for 90 days (both females and males) following the last dose of study drug
  • NOTE: Effective forms of contraception are defined as hormonal oral contraceptives, injectables, patches, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal ligation, condoms with spermicide, or male partner sterilization
  • Able to understand and willing to sign the informed consent form
  • NOTE: A legally authorized representative may consent on behalf of a subject who is otherwise unable to provide informed consent if acceptable to and approved by the site's Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
  • Able to comply with scheduled visits, treatment plans, procedures, and laboratory tests, including serial peripheral blood sampling during the study
  • Willing to provide blood samples for correlative research purposes

Who cannot join

  • Prior therapy with either an IDH inhibitor or selective FGFR inhibitor
  • IDH inhibitors: ivosidenib, FT-2012, etc.
  • FGFR inhibitors: pemigatinib, BGJ-398, TAS-120, ARQ 087, or derazantinib, etc.
  • Progressive disease as best response on current standard-of-care chemotherapy including gemcitabine and cisplatin
  • Known toxicity to standard-of-care chemotherapy including gemcitabine and cisplatin requiring cessation of this therapy
  • Received radiotherapy to metastatic sites of disease =< 2 weeks prior to registration
Show all 46Show fewer
  • Underwent hepatic radiation, chemoembolization, or radiofrequency ablation =< 4 weeks prior to registration
  • Known symptomatic brain metastases requiring steroids
  • NOTE: Subjects with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study entry, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and have radiographically stable disease for at least 3 months prior to registration
  • NOTE: Up to 10 mg per day of prednisone equivalent will be allowed
  • Other active malignancy =< 5 years prior to registration. EXCEPTIONS:
  • Non- melanoma skin cancer unless stage 1a or carcinoma-in-situ of the cervix
  • Breast cancer with ongoing hormone therapy being administered as adjuvant therapy
  • NOTE: If there is a history or prior malignancy, they must not be receiving other specific treatment
  • Major surgery =< 4 weeks prior to registration or have not recovered from post-surgery toxicities
  • Any of the following because this study involves investigational agents whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown:
  • Pregnant women
  • Nursing women
  • Men or women of childbearing potential who are unwilling to employ adequate contraception
  • Arm A: Use of strong CYP3A4 inducers or strong or moderate CYP3A4 inhibitors. In addition, sensitive CYP3A4 substrate medications with a narrow therapeutic window, unless they can be transferred to other medications =< 4 days or 5 half-lives (whichever is shorter) prior to registration
  • Arm B: Use of strong CYP3A4 inducers or inhibitors or moderate CYP3A4 inducers
  • NOTE: Study principal investigator (PI) approval is needed if continued use of CYP3A4 inducers or inhibitors. Approval can be obtained via email (documentation of approval/eligibility needed)
  • For Arm B only: Current evidence of clinically significant corneal (including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and keratoconjunctivitis) or retinal disorder (including but not limited to central serous retinopathy, macular/retinal degeneration, diabetic retinopathy, retinal detachment) as confirmed by ophthalmologic examination
  • Known history and/or current evidence of ectopic mineralization/ calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcification for Arm B only
  • Known history of hypovitaminosis D requiring supraphysiologic doses to replenish the deficiency for Arm B only
  • NOTE: Subjects receiving vitamin D food supplements are allowed
  • Active infection requiring systemic anti-infective therapy or with an unexplained fever > 38.5 degrees Celsius (C) =< 7 days of registration
  • NOTE: At the discretion of the investigator, subjects with tumor fever may be enrolled
  • Any known hypersensitivity to any of the components of ivosidenib or pemigatinib
  • Significant, active cardiac disease =< 6 months prior to registration, including
  • New York Heart Association (NYHA) class III or IV congestive heart failure
  • Myocardial infarction
  • Unstable angina
  • Stroke
  • Have a heart-rate corrected QT interval (using Fridericia's formula) (QTcF) >= 450 msec or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome)
  • Note: Bundle branch block and prolonged QTcF interval are permitted with approval of the medical monitor
  • Taking medications that are known to prolong the QT interval, unless they can be transferred to other medications >= 5 half-lives prior to registration or unless the medications can be properly monitored during the study
  • Note: If equivalent medication is not available, QTcF should be closely monitored
  • Known active hepatitis B (hepatitis B virus [HBV]) or hepatitis C (hepatitis C virus [HCV]) infections, known positive human immunodeficiency virus (HIV) antibody results, or acquired immunodeficiency syndrome (AIDS) related illness
  • NOTE: Subjects with a sustained viral response to HCV or immunity to prior HBV infection will be permitted. Subjects with chronic HBV that is adequately suppressed per institutional practice will be permitted
  • NOTE: HBV, HCV, and/or HIV testing is not required prior to trial registration
  • Any other acute or chronic medical or psychiatric condition, including recent (=< 12 months of registration) or active suicidal ideation or behavior, or a laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
  • Inability or unwillingness to swallow ivosidenib or pemigatinib or have significant gastrointestinal (GI) disorder(s) that could interfere with absorption, metabolism, or excretion
  • NOTE: Gastroesophageal reflux disease under medical treatment is allowed (assuming no drug interaction potential)
  • Have been committed to an institution by virtue of an order issued either by the judicial or administrative authorities
  • Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm

Trial locations and contacts

7 sites in 1 country.

7 sites in 1 country

United States7 sites

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia, 30322

  • Spartanburg Regional Medical Center

    Forest City, North Carolina, 28043

  • M D Anderson Cancer Center

    Houston, Texas, 77030

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259

  • Aurora Cancer Care-Milwaukee West

    Wauwatosa, Wisconsin, 53226

Other trials in United States

About this study

Official title: A Phase I, Multi-Center, Open Label, Dose De-Escalation and Expansion Study of Gemcitabine and Cisplatin With AG120 or Pemigatinib for Advanced Cholangiocarcinoma

This phase I trial studies the side effects and best dose of gemcitabine and cisplatin when given together with ivosidenib or pemigatinib in treating patients with cholangiocarcinoma that cannot be removed with surgery (unresectable) or has spread to other places in the body (metastatic). Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ivosidenib and pemigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine and cisplatin with ivosidenib or pemigatinib may work better in treating patients with cholangiocarcinoma compared to gemcitabine and cisplatin alone.

Read the detailed description

PRIMARY OBJECTIVE:

  1. To evaluate the safety, tolerability, maximum tolerated dose (MTD) and/or recommended phase 2 dose, gemcitabine and cisplatin in combination with either ivosidenib or pemigatinib.

SECONDARY OBJECTIVES:

  1. To evaluate median and progression free survival (PFS) for 6 months per investigator assessment.

II. To evaluate the rate of overall survival (OS) in patients treated with gemcitabine and cisplatin in combination with either ivosidenib or pemigatinib.

III. To describe the overall toxicity and adverse events profile associated with gemcitabine and cisplatin in combination with either ivosidenib or pemigatinib.

IV. To determine the best response profile per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in patients treated with gemcitabine and cisplatin in combination with either ivosidenib or pemigatinib.

CORRELATIVE RESEARCH OBJECTIVE:

  1. To measure plasma 2-hydroxglutarate (2-HG) levels =< 21 days prior to registration and at cycle 4 day 1 (+/- 2 days).

OUTLINE: This is a dose de-escalation study. Patients are assigned to 1 of 2 arms.

ARM A (IDH1 GENE MUTATION): Patients receive ivosidenib orally (PO) on days 1-21, cisplatin intravenously (IV) on days 1 and 8, and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

ARM B (FGFR2 GENE ALTERATION): Patients receive pemigatinib PO on days 1-21, cisplatin IV on days 1 and 8, and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then every 6 months for up to 3 years.

Being tested
Cisplatin, Gemcitabine, Ivosidenib, Pemigatinib
Medical subject headings
Cholangiocarcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CisplatinDrug

    Also called Abiplatin, Blastolem, Briplatin, CDDP

    Given IV

  • GemcitabineDrug

    Also called dFdC, dFdCyd, Difluorodeoxycytidine

    Given IV

  • IvosidenibDrug

    Also called AG-120, Tibsovo

    Given PO

  • PemigatinibDrug

    Also called INCB054828, Pemazyre

    Given PO

Study groups in NCT04088188
Study groupRoleWhat they receive
Arm A (ivosidenib, cisplatin, gemcitabine)ExperimentalPatients receive ivosidenib PO on days 1-21, cisplatin IV on days 1 and 8, and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Receives: Drug: Cisplatin; Drug: Gemcitabine; Drug: Ivosidenib
Arm B (pemigatinib, cisplatin, gemcitabine)ExperimentalPatients receive pemigatinib PO on days 1-21, cisplatin IV on days 1 and 8, and gemcitabine IV on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Receives: Drug: Cisplatin; Drug: Gemcitabine; Drug: Pemigatinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Significant Toxicities

    A significant toxicity is defined as a Dose Limiting Toxicity that is possibly, probably, or definitely related to treatment. DLTs will be evaluated starting in the first cycle of combination treatment and up to 3 weeks of combination treatment. Toxicities will be assessed using the CTEP Active Version of the CTCAE. All patients meeting the eligibility criteria who have signed a consent form and have begun combination treatment will be considered evaluable for significant toxicity. Patients, who do not experience a DLT but withdraw from protocol therapy prior to 3 weeks, will not be evaluable for the primary endpoint. Incidence of significant toxicity at 3 weeks will be estimated separately by arm and will be defined as the number of patients with significant toxicity within 3 weeks of combination treatment divided by the total number of evaluable patients.

    Measured: 3 weeks

Secondary outcomes (5)

  1. Overall Survival

    Overall survival is defined to be the length of time from start of study therapy to death due to any cause. All patients meeting the eligibility criteria that have signed a consent form and begun treatment will be considered evaluable for estimation of the survival distribution. The distribution of overall survival for both arms of the study will be estimated separately using the Kaplan-Meier method.

    Measured: 27 months

  2. Progression Free Survival

    Progression free survival time is defined as the time from the start of study therapy to documentation of disease progression. Patients who die without documentation of progression will be considered to have had tumor progression at the time of death. Patients who are still alive and have not progressed will be censored for progression at the time of the last disease evaluation. The time-to-progression distribution will be estimated separately for both arms, using the Kaplan-Meier method.

    Measured: 24 months

  3. Number of Patients Experiencing Adverse Events

    The number and severity of all adverse events (overall, by dose-level, and by tumor group) will be tabulated and summarized in this patient population. The grade 3+ adverse events will also be described and summarized in a similar fashion.

    Measured: 16 months

  4. Number of Participants Experiencing Toxicities

    The term toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment. Non-hematologic toxicities will be evaluated via the ordinal Common Terminology Criteria (CTC) standard toxicity grading. Hematologic toxicity measures of thrombocytopenia, neutropenia, and leukopenia will be assessed using continuous variables as the outcome measures (primarily nadir) as well as categorization via CTC standard toxicity grading. Overall toxicity incidence as well as toxicity profiles by dose level, patient and tumor site will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.

    Measured: 16 months

  5. Best Response

    Best Response is defined to be the best objective status recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria. Response Evaluation Criteria in Solid Tumors 1.1 criteria will be used for tumor evaluation and patients will be re-evaluated every prior to treatment in cycle 3 and then in odd subsequent cycles. Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population (overall and by tumor group).

    Measured: 15 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Sep 2019
  2. Study start25 Jan 2021
  3. Primary completion1 Dec 2023
  4. Study completion1 Dec 2023

Why it stopped: Low accrual

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
8 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04088188
Sponsor's protocol ID
ACCRU-ICRN-1701
Other IDs
NCI-2019-05811, ACCRU-ICRN-1701, P30CA015083
Status last verified
Apr 2024
First submitted
11 Sep 2019
Last updated
6 May 2024
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Saj F, Bekaii-Saab TS, Javle M, Larson JJ, Borad MJ, Pant S. Phase I results of a multicenter, open-label, dose de-escalation and expansion study of gemcitabine and cisplatin with ivosidenib or pemigatinib for advanced cholangiocarcinoma. Invest New Drugs. 2026 Feb;44(1):48-55. doi: 10.1007/s10637-026-01602-6. Epub 2026 Feb 12.

    PubMed 41678089

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Cisplatin, Gemcitabine and Ivosidenib in people with Advanced Cholangiocarcinoma and Metastatic Cholangiocarcinoma, run by Academic and Community Cancer Research United at 7 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 26 inclusion and 46 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 6 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 2 May 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Significant Toxicities (time frame: 3 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04088188, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2024; AzTrials last refreshed its copy on 8 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in